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OBJECTIVES: Intravenous immunoglobulin (IGIV) made from
chromatography-caprylate methods (IGIV-C, 10%) was associ-
ated with a reduction in validated infections (pneumonia, sinusi-
tis and acute exacerbation of chronic sinusitis) when compared
to IGIV made from solvent-detergent methods (IGIV-SD, 10%)
in patients with primary immunodeﬁciency disease. Our objec-
tive was to determine the cost-effectiveness of IGIV-C.
METHODS: We performed a retrospective economic analysis of
a double-blind, randomized, clinical trial. Participants were ran-
domly assigned to IGIV-C (n = 87) or IGIV-SD (n = 85) and mon-
itored for the development of validated infections over the course
of 9 months. Consumed resources were enumerated including
cost of physician and emergency room visits, medications (pre-
scription and over-the-counter), work productivity losses and
hospitalizations. Resource data was obtained from case report
forms, patient diaries and the trial medication database. Unit
costs were obtained from national costing sources (Thomson’s
Redbook, Health Care Utilization Project database), etc. Pricing
of both IGIV products was the same therefore IGIV acquisition
costs were not included in the analyses. We used a societal per-
spective with indirect costs, measured in 2003 U.S. dollars.
RESULTS: In a multivariate analysis, mean per participant costs
were signiﬁcantly lower between those receiving IGIV-C com-
pared to IGIV-SD for prescription medications (-$302, 95% CI:
-$598, -$6), hospitalization (-$1454, 95% CI: -$1828, -
$1080) and total costs (-$1304, 95% CI: -$1867, -$742). Par-
ticipant costs associated with lost work productivity and
physician visits were similar for both groups (p > 0.10). In sen-
sitivity analyses, using 80% of average wholesale price for
costing prescription medications instead of 95%, the mean per
participant costs remained statistically lower for the IGIV-C
group. CONCLUSIONS: IGIV-C is cost-saving and provides
incremental health beneﬁts therefore it is a dominant strategy
compared to IGIV-SD. Differences in the process of
immunoglobulin manufacturing can lead to meaningful clinical
and economic outcome differences in the care.
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OBJECTIVE: The objective of this study was to evaluate the
resource consumption and outcomes associated with ﬁrst-line
monotherapy for community-acquired pneumonia (CAP), focus-
ing speciﬁcally on the use of erythromycin, azithromycin, clar-
ithromycin, and levoﬂoxacin. METHODS: A retrospective
database analysis was conducted of patients diagnosed with
pneumonia from managed care organizations from January 1995
to April 2002. Linear and logistic regression models were used
to examine associations with treatment success rates and direct
medical costs between antibiotic treatments after controlling for
patient demographics and pneumonia risk factors. RESULTS:
Overall, treatment success rates were high (95.8%), the use of
second antibiotics was uncommon (2.3%), and hospitalizations
were infrequent (2.0%) among the 1952 patients studied. After
controlling for patient characteristics and risk factors, statisti-
cally lower total costs were associated with erythromycin
(92.7% lower), azithromycin (48.7% lower), and clarithromycin
(21.3% lower) relative to levoﬂoxacin, with no difference in
treatment success between groups. Post-hoc analyses assessing
subsets as 1) >50 years of age; 2) presentation of a comorbid
disease state; or 3) a chronic disease score (CDS) above 
the sample’s mean indicated that both erythromycin and
azithromycin were associated with statistically lower total costs
than levoﬂoxacin, while clarithromycin was not signiﬁcantly dif-
ferent. When limiting the assessment to only newer agents,
azithromycin (49.2% lower) and clarithromycin (21.7% lower)
were associated with lower total costs relative to levoﬂoxacin.
Additionally, in subjects with a CDS above the sample’s mean,
only azithromycin was associated with lower total costs (49.2%
lower) relative to levoﬂoxacin, with no differences observed con-
cerning treatment success. CONCLUSIONS: This real-world
analysis of managed care patients found that erythromycin,
azithromycin, and clarithromycin were associated with signiﬁ-
cantly lower total costs than levoﬂoxacin, without differences in
treatment success rates. Following stratiﬁcation based upon
various subset criteria, erythromycin and azithromycin were
observed to have signiﬁcantly lower total costs than levoﬂoxacin.
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OBJECTIVES: International studies have reported the overall
cost per patient associated with severe sepsis. However, there is
a lack of understanding about how the treatment cost and
resource utilization varies with failure of one or more organs.
This study was conducted to: 1) identify cost element ﬂow and
frequency of resource use to estimate aggregated cost for typical
ICU medical and surgical severe sepsis patients with various
organ dysfunctions, and 2) determine the prevalence of type of
organ failures and cost associated with the management in severe
sepsis patients with failure in two organs. METHODS: Retro-
spective review of the GSH administrative database from 1999
to 2002 of ICU severe sepsis patients (n = 889). Sepsis and organ
failure classiﬁcation was based on reported ICD-9-CM codes.
Resource utilization and cost data, through day 28, were
obtained from both ICU and non-ICU cost centers. RESULTS:
A matrix of the frequency of resource utilization and average
cost per resource associated with the severe sepsis treatment 
was generated. Resource categories included: room & board,
nursing, medications, operating room, laboratories, diagnostics,
physical therapy, and organ related treatment. The mean LOS
was 16.6 ± 15 days for all severe sepsis patients. Survivors had
an average 6 days greater LOS than non-survivors. The mean
total cost per severe sepsis patient abstracted was $29,390 ±
$24,673 ($1,594/day) for survivors, $27,837 ± $29,445
($2,268/day) for non-survivors, and $27,548 ± $22,824
($1,620/day) for sepsis patients with 2 acute organ failures.
Highest prevalence among patients with two organ dysfunctions
was Respiratory + (Cardiovascular or Renal) organ failures.
Average hospital mortality of severe sepsis patient was 30.2%.
